Director, Integrated Product Medical Lead; m​/f​/d

Director, Integrated Product Medical Lead (m/f/d) Your Tasks and Responsibilities

The Integrated Product Medical Lead (IPML) is crucial for advancing the Oncology early development portfolio. The IPML creates a significant impact through the successful progression of global development programs and the expansion of our pipeline. The IPML sets the vision and strategic direction for assigned programs, ensuring a medically and clinically sound end‑to‑end development strategy for our products across various modalities, biologies, and indications.

The IPML represents the full value chain, from pre‑D1 up to hand‑over to late‑stage drug development. The IPML builds an end‑to‑end clinical strategy and executes development programs on behalf of Early Clinical Development Oncology (ECDO), providing clinical‑scientific leadership for one or more global development programs with full decision‑making authority. By collaborating with cross‑functional IPT members, the IPML drives the creation and maintenance of a target product and target value profile to maximize the clinical success of development programs and significantly shape the value of the product.

The IPML co‑leads the incorporation of novel assets into the pipeline through supporting internal and external innovation efforts and plays a vital role in shaping functional excellence within ECDO by driving core project, people, and innovative clinical development topics under a peer‑reviewed setting, pushing the boundaries of drug development in collaboration with internal and external researchers.

• Act as the clinical leader and primary clinical representative for global programs, ensuring high quality and speed of functional deliverables.
• Develop a clinical vision for addressing unmet medical needs, considering the molecule’s scientific hypothesis.
• Accountable for timely delivery of milestones, mitigating roadblocks, and empowered to take decisions to effectively execute the clinical strategy.
• Support preclinical evaluation and validation of new oncology assets in line with the Research and Early Development Oncology (RED ONC) strategy.
• Guide preclinical asset development to enable informed clinical development, facilitating go/no‑go decision making.
• Review key study documents, ensuring alignment with clinical development plans and target product profiles.
• Provide comprehensive knowledge of the scientific, development, and regulatory landscape to enable state‑of‑the‑art early precision drug development.
• Proactively interact with academic and industry partners, health authorities, key opinion leaders, and patient advocacy groups.
• Lead and drive ECDO‑initiated strategic initiatives in support of overall ECDO, RED‑ONC, Oncology, and Bayer strategy.
• Independently lead self‑empowered matrix teams, promoting a creative and innovation‑friendly collaboration between clinicians and scientists.
• Foster a culture of ownership and empower others, driving peer accountability across portfolio deliverables.

• Medical excellence: M.D. with 5+ years in direct patient care and board certification within oncology/hematology or associated subspecialties.
• Scientific excellence demonstrated by a track record of relevant research documented in peer‑reviewed publications.
• Outstanding drug development expertise with 3‑5 years of experience, including 2+ years in early drug development.
• Expertise across different biologies and modalities, including small and large molecules.
• Relevant global health authority interactions and current knowledge of regulatory review and responses.
• Ability to independently develop a sound medical strategy and teach others to do so.
• Strong communication and leadership skills, strategic thinking, and good business and external trends insights.
• High energy with focus and vision; self‑motivated with a high sense of ownership and proactive, solution‑oriented approach.
• Fluency in English is mandatory; command of a second major European language, especially German, would be an asset.

Bayer welcomes applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law. We are committed to treating all applicants fairly and avoiding discrimination. Bayer is committed to providing barrier‑free access and support‑facilities for individuals with disabilities - during the application process and beyond.

Applicants with disabilities are encouraged to request any support / equipment they may need via the contact information below.

Switzerland:
Basel‑City:
Basel

Pharmaceuticals

842804